Maxim Group Rates VolitionRx (VNRX) buy, $4 Price Target
Maxim Group reinstates VolitionRx Limited with a Buy rating and a $4 price target, a 227.87% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Maxim Group rated VolitionRx Limited ($VNRX) "buy" with a $4 price target on June 18, 2026.
Since the rating, $VNRX is down 9.8% after 1 week, down 21.0% after 1 month and down 87.4% to date (from the $1.43 close on Jun 18, 2026).
VNRX
VolitionRx Limited
Key Points
- Maxim Group has reinstated VolitionRx Limited with a Buy rating and set a price target of $4.
- Maxim Group's $4 price target implies 227.87% upside from VolitionRx Limited's ($VNRX) current $1.22 share price.
- VolitionRx shares are trading around $1.43, with a 52-week range between $1.3 and $18.8.
- Insiders have sold shares recently, while institutional investors like Lagoda Investment Management have reduced their holdings.
Get $VNRX trade alerts by text
We text you when insiders, Congress or big funds trade $VNRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated VolitionRx Limited alert may contain errors. Disclosures
Maxim Group has reinstated its coverage on VolitionRx Limited, trading under the ticker VNRX on the NYSE American, with a Buy rating. Analyst Michael Okunewitch set a price target of $4 on June 18, 2026. This move highlights a positive outlook for the company as it currently trades around $1.43 per share.
Maxim Group vs. the S&P 500
Hypothetical returns from Maxim Group's disclosed trades, not real profit or advice. How we model this.
VolitionRx Limited Stock Up 369.2%
Shares of NYSE American:VNRX are trading near $1.43. VolitionRx Limited has a market cap of about $16.57 million. The stock has a 52-week low of $1.3 and a high of $18.8. Its 50-day moving average is $2.46, while the 200-day moving average stands at $5.85. The current ratio is 0.333, indicating limited short-term liquidity, and the quick ratio is 0.247.
$VNRX price target
VolitionRx Limited daily closes and this analyst's $4 target. Not advice.
Other Institutional Activity in VolitionRx Limited
Lagoda Investment Management, L.P. significantly reduced its holdings in VolitionRx, cutting down by 10.65 million shares to hold 807,450 shares worth approximately $3.26 million. Geode Capital Management, LLC also reduced its position by 902,482 shares, ending with 61,504 shares valued at $248,510. On the other hand, Vanguard Capital Management LLC and Luminus Management LLC each established positions, holding 50,684 and 49,750 shares valued at $204,762 and $200,990, respectively.
Insider Buying and Selling at VolitionRx Limited
Recent insider activity at VolitionRx shows several executives selling shares in March 2026. Nicholas Plummer, GC at Volition Diagnostics, sold 7,003 shares on March 17, while Chief Scientific Officer Jacob Vincent Micallef sold 5,310 shares on the same day. Other insiders, including Secretary Rodney Gerard Rootsaert and Chief Commercial Officer Gael Forterre, also sold shares.
Analysts Set New Price Targets
On June 18, 2026, Maxim Group reinstated VolitionRx with a Buy rating and a $4 price target. Previously, HC Wainwright & Co. maintained a Buy rating with a $1 target on April 2, 2026. D. Boral Capital has consistently maintained a Buy rating with targets ranging from $3 to $5 over the past months. The consensus target price is $20.21, based on four analyst opinions.
About VolitionRx Limited
VolitionRx Limited is a healthcare company specializing in medical devices, headquartered in Henderson, Nevada. It develops blood tests for cancer detection and monitoring, including the Nu.Q Vet for animals and Nu.Q Nets for diseases like sepsis. The company also offers solutions like Nu.Q Discover for profiling nucleosomes and Capture-PCR for isolating tumor-derived DNA. Under the leadership of CEO Cameron Reynolds, VolitionRx employs 67 people.
Bottom Line
Maxim Group's Buy rating and $4 target suggest optimism for VolitionRx's future. Investors watch these ratings closely, though it's important to remember that analyst opinions are just one piece of the puzzle. As a reminder, these insights are backward-looking and reflect the analysts' perspective as of their issuing dates.
Related Filing Alerts
Source: Maxim Group's rating change on $VNRX (Jun 18, 2026). Written by software, not financial advice. How we make alerts